Plasma sphingomyelins are associated with cognitive progression in alzheimer's disease

Journal of Alzheimer's Disease

Volumn 27, Issue 2, 2011, Pages 259-269

  Mielke, Michelle M ^a,b   Haughey, Norman J ^a   Bandaru, Veera Venkata Ratnam ^a   Weinberg, Danielle D ^a   Darby, Eveleen ^c   Zaidi, Noman ^c   Pavlik, Valory ^c   Doody, Rachelle S ^c   Lyketsos, Constantine G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; biomarker; ceramide; dihydroceramide; dihydrosphingomyelin; plasma; sphinganine; sphingomyelin; sphingosine

Indexed keywords

CERAMIDE; DIHYDROCERAMIDE; DIHYDROSPHINGOMYELIN; SPHINGOLIPID; SPHINGOMYELIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ALZHEIMER'S DISEASE ASSESSMENT SCALE COGNITIVE SUBSCALE; ARTICLE; CLINICAL ASSESSMENT; CLINICAL DEMENTIA RATING SUM OF BOXES SCALE; COGNITION; COGNITIVE DEFECT; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY ANALYSIS;

EID: 81855168404     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-110405     Document Type: Article

References (41)

1. Doody RS, Massman P, Dunn JK (2001) A method for estimating progression rates in Alzheimer disease. Arch Neurol 58, 449-454. (Pubitemid 32217462)
2. Johnsen S, Hughes S, Bullock R, Hindmarch I (2003) Prediction of the rate of decline in cognitive function in Alzheimer's disease: A model based on simple demographic data and widely used rating scales. Dement Geriatr Cogn Disord 16, 276-282. (Pubitemid 37188123)
3. Tschanz JT, Corcoran CD, Schwartz S, Treiber K, Green RC, Norton MC, Mielke MM, Piercy K, Steinberg M, Rabins PV, Leoutsakos JM, Welsh-Bohmer KA, Breitner JC, Lyketsos CG (2011) Progression of cognitive, functional, and neu-ropsychiatric symptom domains in a population cohort with Alzheimer dementia: The cache county dementia progression study. Am J Geriatr Psychiatry 19, 532-542.
4. Rountree SD, Chan W, Pavlik VN, Darby EJ, Siddiqui S, Doody RS (2009) Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther 1, 7.
5. Doody RS, Pavlik V, Massman P, Rountree S, Darby E, Chan W (2010) Predicting progression of Alzheimer's disease. Alzheimers Res Ther 2, 2.
6. Haughey NJ, Bandaru VV, Bae M, Mattson MP (2010) Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis. Biochim Biophys Acta 1801, 878-886.
7. Mielke MM, Lyketsos CG (2010) Alterations of the sphin-golipid pathway in Alzheimer's disease: New biomarkers and treatment targets? Neuromolecular Med 12, 331-340.
8. London E, Brown DA (2000) Insolubility of lipids in triton X-100: Physical origin and relationship to sphingolipid/cholesterol membrane domains (rafts). Biochim Biophys Acta 1508, 182-195.
9. Hur JY, Welander H, Behbahani H, Aoki M, Franberg J, Winblad B, Frykman S, Tjernberg LO (2008) Active gamma-secretase is localized to detergent-resistant membranes in human brain. FEBS J 275, 1174-1187. (Pubitemid 351342213)
10. Andrieu-Abadie N, Gouaze V, Salvayre R, Levade T (2001) Ceramide in apoptosis signaling: Relationship with oxidative stress. Free Radic Biol Med 31, 717-728. (Pubitemid 32835252)
11. Puglielli L, Ellis BC, Saunders AJ, Kovacs DM (2003) Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. J Biol Chem 278, 19777-19783. (Pubitemid 36799164)
12. Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, Troncoso JC, Mattson MP (2004) Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci USA 101, 2070-2075. (Pubitemid 38229016)
13. Jana A, Pahan K (2004) Fibrillar amyloid-beta peptides kill human primary neurons via NADPH oxidase-mediated activation of neutral sphingomyelinase Implications for Alzheimer's disease. J Biol Chem 279, 51451-51459. (Pubitemid 40017893)
14. Kalvodova L, Kahya N, Schwille P, Ehehalt R, Verkade P, Drechsel D, Simons K (2005) Lipids as modulators of proteolytic activityofBACE: Involvementofcholesterol, gly-cosphingolipids, and anionic phospholipids in vitro. J Biol Chem 280, 36815-36823. (Pubitemid 41587762)
15. Mattson MP, Cutler RG, Jo DG (2005) Alzheimer peptides perturb lipid-regulating enzymes. Nat Cell Biol 7, 1045-1047.
16. He X, Huang Y, Li B, Gong CX, Schuchman EH (2010) Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol Aging 31, 398-408.
17. Soderberg M, Edlund C, Alafuzoff I, Kristensson K, Dallner G (1992) Lipid composition in different regions of the brain in Alzheimer's disease/senile dementia of Alzheimer's type. J Neurochem 59, 1646-1653.
18. Gottfries CG, Karlsson I, Svennerholm L (1996) Membrane components separate early-onset Alzheimer's disease from senile dementia of the Alzheimer type. Int Psychogeriatr 8, 365-372. (Pubitemid 27067586)
19. Pettegrew JW, Panchalingam K, Hamilton RL, McClure RJ (2001) Brain membrane phospholipid alterations in Alzheimer's disease. Neurochem Res 26, 771-782. (Pubitemid 32845968)
20. Mielke MM, Bandaru VV, Haughey NJ, Rabins PV, Lyket-sos CG, Carlson MC (2010) Serum sphingomyelins and ceramides are early predictors of memory impairment. Neu-robiol Aging 31, 17-24.
21. Mielke MM, Haughey NJ, Ratnam Bandaru VV, Schech S, Carrick R, Carlson MC, Mori S, Miller MI, Ceritoglu C, Brown T, Albert M, Lyketsos CG (2010) Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. Alzheimers Dement 6, 378-385.
22. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944. (Pubitemid 14076461)
23. Doody R, Pavlik V, Massman P, Kenan M, Yeh S, Powell S, Cooke N, Dyer C, Demirovic J, Waring S, Chan W (2005) Changing patient characteristics and survival experience in an Alzheimer's center patient cohort. Dement Geriatr Cogn Disord 20, 198-208. (Pubitemid 41191638)
24. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
25. Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, Sano M, Bieliauskas L, Geldmacher D, Clark C, Thal LJ (1997) Development of cognitive instruments for use in clinical trials of antidementia drugs: Additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11 (Suppl 2), S13-S21.
26. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 140, 566-572. (Pubitemid 12124384)
27. Morris JC (1997) Clinical dementia rating: areliable and valid diagnostic and staging measure for dementiaof the Alzheimer type. Int Psychogeriatr 9 (Suppl 1), 173-176; discussion 177-178. (Pubitemid 28045357)
28. Pavlik VN, Doody RS, Massman PJ, Chan W (2006) Influence of premorbid IQ and education on progression of Alzheimer's disease. Dement Geriatr Cogn Disord 22, 367-377. (Pubitemid 44651453)
29. Bandaru VV, Troncoso J, Wheeler D, Pletnikova O, Wang J, Conant K, Haughey NJ (2009) ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain. Neurobiol Aging 30, 591-599.
30. Grimm MO, Grimm HS, Patzold AJ, Zinser EG, Halonen R, Duering M, Tschape JA, De Strooper B, Muller U, Shen J, Hartmann T (2005) Regulation of cholesterol and sphin-gomyelin metabolism by amyloid-beta and presenilin. Nat Cell Biol 7, 1118-1123.
31. Gulbins E, Kolesnick R (2003) Raft ceramide in molecular medicine. Oncogene 22, 7070-7077. (Pubitemid 37386676)
32. Lee JT, Xu J, Lee JM, Ku G, Han X, Yang DI, Chen S, Hsu CY (2004) Amyloid-beta peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J Cell Biol 164, 123-131. (Pubitemid 38082463)
33. Han X, D MH, McKeel DW Jr., Kelley J, Morris JC (2002) Substantial sulfatide deficiencyand ceramideelevationinvery early Alzheimer's disease: Potential role in disease pathogen-esis. J Neurochem 82, 809-818.
34. Satoi H, Tomimoto H, Ohtani R, Kitano T, Kondo T, Watanabe M, Oka N, Akiguchi I, Furuya S, Hirabayashi Y, Okazaki T (2005) Astroglial expression of ceramide in Alzheimer's disease brains: A role during neuronal apoptosis. Neuroscience 130, 657-666. (Pubitemid 39601439)
35. Byrdwell WC, Perry RH (2006) Liquid chromatography with dual parallel mass spectrometry and (31) P nuclear magnetic resonance spectroscopy for analysis of sphingomyelin and dihydrosphingomyelin I. Bovine brain and chicken egg yolk. J Chromatogr A 1133, 149-171. (Pubitemid 44573167)
36. Tirri LJ, Ayengar NK, Lipton LC, Chatterjie N, Brockerhoff H (1978) Studies on the hydrogen belts of membranes: III. Glycerol permeability of dihydrosphingomyelin-cholesterol membranes. Lipids 13, 267-269. (Pubitemid 8315549)
37. Hammad SM, Pierce JS, Soodavar F, Smith KJ, Al Gad-ban MM, Rembiesa B, Klein RL, Hannun YA, Bielawski J, Bielawska A (2010) Blood sphingolipidomics in healthy humans: Impact of sample collection methodology. J Lipid Res 51, 3074-3087.
38. Ichi I, Nakahara K, Miyashita Y, Hidaka A, Kutsukake S, Inoue K, Maruyama T, Miwa Y, Harada-Shiba M, Tsushima M, Kojo S (2006) Association of ceramides in human plasma with risk factors of atherosclerosis. Lipids 41, 859-863. (Pubitemid 44788907)
39. Nelson JC, Jiang XC, Tabas I, Tall A, Shea S (2006) Plasma sphingomyelin and subclinical atherosclerosis: Findings from the multi-ethnic study ofatherosclerosis. Am J Epidemiol 163, 903-912.
40. Summers SA (2010) Sphingolipids andinsulinresistance:The five Ws. Curr Opin Lipidol 21, 128-135.
41. Blachnio-Zabielska AU, Pulka M, Baranowski M, Nikola-juk A, Zabielski P, Gorska M, Gorski J (2011) Ceramide metabolism is affected by obesity and diabetes in human adipose tissue. J Cell Physiol, doi: 10. 1002/jcp. 22745